We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions about Oxford Biomedica Plc (OXB) over the past week reveal a heightened focus on the possibility of a takeover, amidst uncertainty surrounding the company's share price and recent trading patterns. Many investors express concerns over perceived manipulation of the stock price, with comments suggesting that there seems to be a cap on the share price, limiting upward movement and potentially making the company more attractive for a suitor. Notably, one commenter stated, "the behavior of the company hasn't appeared to be helping their share price," reflecting frustration over stagnant growth and market performance.
Financially, there is optimism amongst investors regarding potential revenue growth, with predictions of around £180 million in sales for next year anticipated. However, there is also skepticism about future valuations and potential acquisition prices, with quotes like "a bid of £7-9 being anything close to a successful bid" illustrating divided sentiment on share value realization in the event of a takeover. Overall, while there are discussions about the benefits of remaining independent and growing as a key player in the CDMO sector, the consensus leans towards apprehension regarding the company's vulnerability to opportunistic bids, as highlighted by one investor's remarks regarding "time will tell—both with the takeover hypothesis and the price."
Investors are observing the ongoing negotiations and strategic moves by major shareholders and potential acquirers, with many eager for clarity on OXB’s trajectory and market positioning as the year draws to a close.
Show more
Oxford Biomedica Plc (OXB), a company leading in cell and gene therapy contract development and manufacturing, recently announced an update regarding its total voting rights, which now stands at 105,938,933 ordinary shares as of November 30, 2024. This follows previous disclosures earlier in the month, confirming a consistent share structure without treasury shares. The total number of voting rights is crucial for shareholders who need to assess their interests in the company, in accordance with Financial Conduct Authority regulations.
In a strategic move, OXB has appointed Colin Bond as a Non-Executive Director, effective January 1, 2025, as part of the company's succession planning on its board. Bond brings substantial experience from the biopharma sector, having previously served as CFO of Sandoz, which strengthens OXB's governance as it navigates its growth trajectory. Furthermore, Oxford Biomedica is hosting a free webinar on December 9, 2024, focusing on innovations in viral vector manufacturing, underscoring its commitment to advancing research and development through automation technologies.
Show more
Just been watching the cinema film about Trump's early days..quite some life he has led. |
Worth keeping an eye on Milei/Argentina. It may be the start of something broader, particularly if Musk, sorry, Trump, gets in. |
We’re all singing from pretty much the same song sheet here. |
How many "workers" in the UK receive a cheque each month or if they have an emergency write out a cheque? Not many I suggest. |
I hate my phone keyboard |
March, notatch. |
Read the thread to get an idea. You'll need to go back to Match to get the full story. |
is this a good share |
FT250 inclusion now feels like a probability rather than a possibility. |
So the auction trade to end there was both 12 month highest intraday and closing price and on good volume. |
Apparently you need to be paid by cheque once a month to be a working person. |
Without going into politics, it appears Sir Starmer's very prestigious previous life is now causing problems in his current role as Prime Minister. |
“Speaking to broadcasters in Samoa, Keir Starmer said he would not use the term-‘working people’-for people who had income from assets such as shares or property. “They wouldn’t come within my definition,” he said. Downing Street hastily clarified that the prime minister did not mean people who owned small amounts of, for example, stocks or shares.” |
Unknown unknowns Dom. |
More effort needed to promote Boston part? Big pharma 'feel safer' buying in the good ole US of A. |
Reading my newsfeed this morning I was distracted by this:- |
Back to OXB and earlier in the year we were all curious about why Frank had become chairman of ArcticZymes and if there was something brewing there. |
Yes i agree with all that Harry.It seems inevitable that Labour will repeat some,if not many,of the mistakes witnessed in the 70s.The road to economic ruin is invariably littered with apparently good socialist intentions.Thereagai |
It's very hard to compare SJ, as until quite recently the US basically had 2 conservative parties. I'm sure you know but early days Ronald Reagan was a card carrying democrat and when asked why he changed, he replied that he hadn't changed it was the democrats who had. Go back even further and the republicans are the abolitionists and hold power in what are now the democratic strongholds of the north east. |
It's far from certain that the US election result will be a smooth uncontested affair and there could well be 10 days of uncertainty hanging over markets following bonfire night on 5th November.The polls are nudging in Trump's favour and discussions i've had with American tourists in various European localities over the last year have on balance pointed in that direction.Kamala Harris's policies are pretty radical.For example,she suggests reforming capital gains tax to be taxed as income,some of her policies are right out of the muted Rachel Reeves handbook.(What a farce waiting for this UK budget has become).I'm not surprised Labour party members are hanging round Democratic conventions,they could be bedfellows. |
Or one of them maybe? (we have 4 in P3). |
Harry, good find. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions